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University of Utah, Salt Lake City, UT 84132, USAInvestigations of anti-HIV-1 human hematopoietic stem/
progenitor cell (HSPC)-based gene therapy have been per-
formed by HIV-1 challenge after the engraftment of gene-
modified HSPCs in humanized mouse models. However,
the clinical application of gene therapy is to treat HIV-1-in-
fected patients. Here, we developed a new method to investi-
gate an anti-HIV-1 HSPC-based gene therapy in humanized
mice previously infected with HIV-1. First, humanized mice
were infected with HIV-1. When plasma viremia reached
>107 copies/mL 3 weeks after HIV-1 infection, the mice
were myeloablated with busulfan and transplanted with
anti-HIV-1 gene-modified CD34+ HSPCs transduced with a
lentiviral vector expressing two short hairpin RNAs
(shRNAs) against CCR5 and HIV-1 long terminal repeat
(LTR), along with human thymus tissue under the kidney
capsule. Anti-HIV-1 vector-modified human CD34+ HSPCs
successfully repopulated peripheral blood and lymphoid tis-
sues in HIV-1 previously infected humanized mice. Anti-
HIV-1 shRNA vector-modified CD4+ T lymphocytes showed
selective advantage in HIV-1 previously infected humanized
mice. This new method will be useful for investigations of
anti-HIV-1 gene therapy when testing in a more clinically
relevant experimental setting.Received 11 November 2017; accepted 26 November 2017;
https://doi.org/10.1016/j.omtm.2017.11.008.
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Hematopoietic stem/progenitor cell (HSPC)-based gene therapy to
reconstitute an HIV-1-infected patient’s immune system with genet-
ically engineered, HIV-resistant HSPCs and their progenies has the
potential to provide a long-term HIV-1 control without daily drug
treatment or to achieve an HIV/AIDS cure.1–7 Similar to the one
case of an HIV-1 cure achieved by transplants of CCR5D32/D32
homozygous HIV-1-resistant donor bone marrow (BM) cells in an
HIV-infected patient,8–11 anti-HIV-1 HSPC gene therapy aims to
treat an HIV-1-infected patient by repopulating HIV-1-resistant
HSPCs and their progenies.Molecular Therapy: Method
This is an open access article under the CC BY-NCVarious anti-HIV-1 genes have been developed to genetically protect
human CD34+ HSPCs and their progenies.4,5,12–29 Previously, in vivo
investigations of these anti-HIV-1 genes have been performed by viral
challenge after transplantation of anti-HIV-1 gene-modified HSPCs
in immunodeficiency mice.15,30–38 The experimental design allowed
us to examine the engraftment of anti-HIV-1 gene-modified HSPCs
without confounding HIV-1 pathogenic effects. Subsequently,
the mice are challenged with HIV-1 to examine the protection of
anti-HIV-1 gene-modified immune cells. Using this protocol, we
demonstrated that human CD34+ HSPCs transduced by an anti-
HIV-1 lentiviral vector expressing dual short hairpin RNAs
(shRNAs) targeting CCR5 (sh1005) and HIV-1 long terminal repeat
(LTR) (sh516) successfully reconstituted anti-HIV-1 vector-modified
multi-lineage hematopoietic cells in humanized BM , liver, and
thymus (BLT)-transplanted mice; we also demonstrated the selective
advantage of the anti-HIV-1 dual shRNA gene expressing CD4+ T
lymphocytes after an HIV-1 challenge in the reconstituted mice.15
However, it is unknown whether the anti-HIV-1 gene-modified
HSPCs can engraft, differentiate into mature hematopoietic cells,
and be protected in humanized mice previously infected with HIV-1.
In this report, our primary goal was to establish a new method to
examine an anti-HIV-1 HSPC-based gene therapy strategy in human-
ized mice previously infected with HIV-1. First, we prepared human-
ized mice by transplanting human fetal liver-derived CD34+ HSPCs
into irradiated neonatal NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice. Humanized mice were subsequently infected with HIV-1.
When plasma viremia reached >107 copies/mL, HIV-1-infected hu-
manized mice were preconditioned with busulfan and transplanteds & Clinical Development Vol. 9 June 2018 ª 2017 The Authors. 23
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. A New Method to Test an Anti-HIV-1 HSPC-Based Gene Therapy in Humanized Mice Previously Infected with HIV-1
Neonatal NSG mice (1–3 days old) were irradiated at 125 cGy and transplanted with human fetal liver-derived CD34+ HSPCs (0.5  105–1.0  105 cells per mouse) by an
intrahepatic injection. Human hematopoietic cell reconstitution was examined in peripheral blood at 10 weeks. Humanized mice were infected with CCR5-tropic HIV-1NFNSX
at a dose of 200 ng of p24 through retro-orbital vein plexus at 11 weeks. Plasma viral load was measured at week 3 post-HIV-1 infection. Humanized mice were pre-
conditioned with busulfan (35 mg/kg) for myeloablation by an intraperitoneal injection. Human fetal liver-derived CD34+ HSPCs (0.5 106) were transduced with an anti-HIV-
1 lentiviral vector expressing short hairpin RNAs against human CCR5 (sh1005) and HIV-1 LTR (sh516) expressing EGFP. The other half of the CD34+ HSPCs (0.5  106)
were transduced with a control lentiviral vector expressingmCherry without shRNA. Transduced CD34+HSPCsweremixed after the vector transduction and transplanted by
a retro-orbital vein plexus injection and with a piece of human thymus under the mouse kidney capsule. Reconstitution of vector-modified human hematopoietic cells was
examined in peripheral blood 6–10 weeks and in lymphoid tissues 12 weeks after vector-modified CD34+ HSPC transplant.
Molecular Therapy: Methods & Clinical Developmentwith anti-HIV-1 gene-modified, human fetal liver-derived CD34+
HSPCs and human thymus tissue from the same donor to repopulate
HIV-1-resistant, gene-modified immune cells in lymphoid organs in
the HIV-1 previously infected humanized mice. Using this new
experimental method, we evaluated the engraftment of the dual
shRNAs, CCR5 (sh1005) and HIV-1 LTR (sh516), modified HSPCs,
differentiation into mature hematopoietic cells, tissue reconstitution,
and the selective advantage of CD4+ T lymphocytes in the HIV-1 pre-
viously infected humanized mice.
RESULTS
Preparation of HIV-1-Infected Humanized NSG Mice
We investigated a new method to test anti-HIV-1 HSPC-based gene
therapy in humanizedmice previously infected withHIV-1 (Figure 1).
To reconstitute HIV-1 target human hematopoietic cells, neonatal
NSG mice (1–3 days old) were irradiated (125 cGy) and transplanted
with human fetal liver-derived CD34+ HSPCs from 5 donors
(0.5  105–1.0  105 cells per mouse) by an intrahepatic injection.
Human multi-lineage hematopoietic cells (CD45+ hematopoietic,
CD3+ T lymphocyte and CD19+ B lymphocyte, and CD4+ T lympho-
cyte and CD8+ T lymphocyte populations) were reconstituted in24 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201peripheral blood 10 weeks after CD34+ HSPC transplant, determined
by monoclonal antibody staining and multi-color flow cytometric
analysis (Figure 2). Humanized mice were divided to create 2 groups
with similar percentage levels of CD45+, CD3+ CD19+, and CD4+
CD8+ cell reconstitution and equally divided among donors (Figure 2,
lower panels). Group 1 mice (n = 11) were infected with CCR5-tropic
HIV-1NFNSX (200 ng of p24 Gag) intravenously via retro-orbital vein
plexus 11 weeks after CD34+ HSPC transplant. Group 2 mice (n = 12)
were used as a non-HIV-1-infected control. Plasma viral load reached
an average of 1.25  107 copies/mL ± 1.48  107 SD 3 weeks after
HIV-1 injection.
Transplantation of Anti-HIV-1 Gene Vector-Transduced HSPCs
in HIV-1 Previously Infected Humanized Mice
HIV-1-infected (n = 11) and HIV-1-uninfected (n = 12) human-
ized mice were myeloablated by an intraperitoneal injection of
busulfan (35 mg/kg) 3 weeks after HIV-1 injection. To avoid po-
tential problems caused by human leukocyte antigen (HLA)
mismatch, cryopreserved, human fetal liver-derived CD34+ HSPCs
from the same donors were thawed and transduced with the anti-
HIV-1 dual shRNA sh1005/sh516 vector (EGFP marked) or the8
Figure 2. Human Hematopoietic Cell Reconstitution in Humanized Mice
Reconstitution of multi-lineage human hematopoietic cells was analyzed in peripheral blood in humanized mice 10 weeks after CD34+ HSPC injection in neonatal NSG
mice. Representative flow plots show the human CD45+ hematopoietic population with forward scatter (FSC), human CD3+ T lymphocyte and CD19+ B lymphocyte
population, and CD4+ T lymphocyte and CD8+ T lymphocyte population (upper panels). Humanized NSG mice were divided into 2 groups based on similar distributions of
%CD45+, %CD3+, %CD19+, %CD4+, and %CD8+ human cell reconstitutions (lower panels). Group 1 mice were infected with CCR5-tropic HIV-1NFNSX (200 ng of p24
Gag) 11 weeks after the CD34+ HSPC transplant. Group 2 mice were mock. The horizontal bars represent the mean. The vertical bars represent the SE. NS, not significant.
www.moleculartherapy.orgno-shRNA control vector (mCherry marked). After vector trans-
duction overnight, vector-transduced cells (0.5  106 cells) were
mixed at a 1:1 ratio and transplanted intravenously via retro-
orbital vein plexus, along with a cryopreserved, donor-matched
human thymus tissue piece under the kidney capsule to create a
human thymus implant, as previously described.15,28,34,39,40 The
efficiencies of vector transduction in CD34+ HSPCs (n = 5) were
determined by %EGFP expression at 72.92 ± 10.84 (% ± SD)
and by %mCherry expression at 73.28 ± 18.98 (% ± SD) in an
aliquot culture with cytokine stimulation (stem cell factor [SCF],
interleukin-3 [IL-3], and IL-6 at 50 ng/mL each) 3 days after vector
transduction.
Repopulation of Anti-HIV-1 Gene-Modified Human
Hematopoietic Cells in HIV-1 Previously Infected Humanized
Mice
Multi-lineage hematopoietic cell repopulation of EGFP+ or
mCherry+ vector-modified cells was initially evaluated in periph-
eral blood 6 weeks after vector-modified CD34+ HSPC transplant
(Figure 3). EGFP+ or mCherry+ expressing cells were identified
in human CD45+ hematopoietic cells, CD3+ T lymphocytes
and CD19+ B lymphocytes, and CD4+ T lymphocytes and CD8+
T lymphocytes in peripheral blood in both HIV-1-infected and
non-HIV-1-infected humanized mice. There was statistically
significant difference between %EGFP and %mCherry in human
CD4+ T lymphocytes in HIV-1 infected humanized mice
(p < 0.05), but not in other lineages at this earliest time point
(p > 0.05, paired Student’s t test).MolecSelective Advantage of Anti-HIV-1Gene Vector-ModifiedHuman
Hematopoietic Cells in HIV-1 Pre-infected Humanized Mice
Kinetics of %EGFP and %mCherry expressing CD4+ T lymphocytes
were monitored in peripheral blood from 6 to 10 weeks after vec-
tor-modified CD34+ HSPC transplant. %EGFP increased more than
%mCherry in CD4+ T lymphocytes in the HIV-1 previously infected
humanized mice (p ˂ 0.0001, group-time interaction from a linear
mixed-effects model) (Figure 4B). There were no significant differ-
ences in the kinetics of %EGFP and %mCherry expression in CD4+
T lymphocytes in HIV-1-uninfected humanized mice (Figure 4A)
and CD8+ T lymphocytes in both uninfected and HIV-1 pre-infected
humanized mice (p > 0.05, group-time interaction from a linear
mixed-effects model) (Figures 4C and 4D). We then analyzed tissue
repopulation 12 weeks after vector-modified CD34+ HSPC trans-
plant. The mean %EGFP was higher than the mean %mCherry+ in
CD4+ T lymphocytes in BM, lung, and gut in the HIV-1 previously
infected humanized mice (Figure 5; Figure S1), suggesting that anti-
HIV-1 dual sh1005/sh516 vector-modified CD4+ T lymphocytes
were positively selected by HIV-1-induced selective pressure in
HIV-1 previously infected humanized mice. Viral load, however,
was maintained in all HIV-1 previously infected humanized mice
12 weeks after anti-HIV-1 gene vector-modified CD34+ HSPC trans-
plant (2.35 107 ± 4.10 107 copies/mL ± SD). Because each animal
was reconstituted with not only EGFP+ anti-HIV-1 gene vector-
modified cells, but also cells marked withmCherry no-shRNA control
vector and unmodified cells, the maintenance of viral load was ex-
pected. Altogether, these results demonstrated anti-HIV-1 dual
sh1005/sh516 vector-modified HSPCs were able to engraft andular Therapy: Methods & Clinical Development Vol. 9 June 2018 25
Figure 3. Repopulation of Vector-Modified Human Hematopoietic Cells in HIV-1 Previously Infected Humanized Mice
Humanized NSG mice (group 1 = HIV-1-infected) and (group 2 = HIV-1-uninfected) were preconditioned with busulfan (35 mg/kg) and transplanted with an equal mix of donor-
matchedanti-HIV-1gene (sh1005/sh516) vectororno-shRNAcontrol vector-modified fetal liverCD34+HSPCs3weeksafterHIV-1 challengewithhuman thymus tissue transplant
under the kidney capsule. Both %EGFP+ and %mCherry+ expression were analyzed in human CD45+ hematopoietic cells, CD3+ T lymphocytes, and CD19+ B lymphocytes in
peripheral blood 6weeks after vector-modifiedCD34+HSPC transplant by flowcytometric analysis. A representative flowplot is shownon the topof each graph. The graph shows
%EGFP+ (closed) and %mCherry+ (open) cells from all mice. The horizontal bars represent the mean. The vertical bars represent the SE. *p < 0.05. NS, not significant.
Molecular Therapy: Methods & Clinical Developmentdifferentiate into mature lymphocytes in the presence of HIV-1 infec-
tion. The anti-HIV-1 dual sh1005/sh516 vector-modified CD4+ T
lymphocytes were positively selected over unprotected cells in the
HIV-1 previously infected humanized mice.
CCR5 Downregulation
The level of CCR5 expression was compared in EGFP+ and mCherry+
CD4+ T lymphocytes in tissues 12 weeks after vector-modified CD34+
HSPC transplant. The level of CCR5 expression in the EGFP+ CD4+ T
lymphocytes was reduced relative to that of the control mCherry+
CD4+ T lymphocytes in tissues in HIV-1-uninfected humanized
mice (Figure 6; Figure S2), similar to our previously published re-
sults.15,28 In humanized mice previously infected with HIV-1, CCR5
expression was reduced in EGFP+ CD4+ T lymphocytes. In addition,
CCR5 expression was reduced in control mCherry+ CD4+ T lympho-
cytes. This could be due to HIV-1-mediated depletion of unprotected26 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201mCherry+ CD4+ T lymphocytes in HIV-1 previously infected human-
ized mice. Therefore, we did not observe a difference in relative CCR5
expression levels in EGFP+ and mCherry+ CD4+ T lymphocytes.
DISCUSSION
In this study, we developed a new method to test an anti-HIV-1
HSPC-based gene therapy in HIV-1 previously infected humanized
mice. The practical clinical application of anti-HIV-1 HSPC-based
gene therapy is to treat HIV-1-infected patients.5,41–44 Thus, it is
important to examine anti-HIV-1 HSPC-based gene therapy strate-
gies in animals already infected with HIV-1.
In our new method, we first infected humanized mice with HIV-1.
After the establishment HIV-1 infection, determined by viremia,
HIV-1-infected humanized mice were treated with busulfan for
myeloablative conditioning and transplanted with anti-HIV-18
B D 
A   C Figure 4. Selective Advantage of Anti-HIV-1 shRNA-
Modified Human CD4+ T Lymphocytes in Peripheral
Blood in HIV-1 Pre-infected Humanized Mice
Kinetics of %EGFP+ and %mCherry+ populations were
compared in human peripheral blood CD4+ T lympho-
cytes in (A) HIV-1-uninfected and (B) HIV-1-infected
humanized mice and in CD8+ T lymphocytes in (C) HIV-1-
uninfected and (D) HIV-1-infected humanizedmice from 6
to 10 weeks after vector-modified CD34+ HSPC trans-
plant. The upper panels show data from all mice. The
lower panels show line graphs for the mean percentages
of EGFP+ and mCherry+ CD4+ T lymphocytes. The hori-
zontal bars represent the mean. The vertical bars repre-
sent the SE. A linear mixed-effects model was used to
evaluate statistical differences in log-transformed EGFP
and mCherry marker levels over time across HIV-1 status.
****p < 0.0001. NS, not significant.
www.moleculartherapy.orggene-modified HSPCs. Using this protocol, we were able to evaluate
the engraftment of anti-HIV-1 gene vector-modified HSPCs, differ-
entiation, tissue reconstitution, and selective advantage of anti-
HIV-1 gene-modified cells in HIV-1 previously infected humanized
mice. This new in vivo experimental method is more clinically rele-
vant than previous experimental procedures in which anti-HIV-1
gene-modified HSPCs are first transplanted in uninfected humanized
mice and subsequently challenged with HIV-1 to assess the efficacy of
anti-HIV-1 reagents.
Human HSPCs were genetically engineered with the lentiviral vector
expressing two anti-HIV-1 shRNAs: sh1005 directed to CCR5 and
sh516 directed to HIV-1 LTR R region sequences.15 The repopula-
tion, CCR5 downregulation, and selective advantage of anti-HIV-1
gene-modified cells in humanized mice already infected with HIV-1Molecular Therapy: Methodwere comparable to our previously published
post-infection results.15,28,34 Our new results
demonstrated that the anti-HIV-1 dual
sh1005/sh516 vector-modified HSPCs success-
fully engrafted and differentiated into the
HIV-1-resistant progeny CD4+ T cells and
then selected from HIV-1-induced T cell
loss in humanized mice already infected with
HIV-1. To our knowledge, this is the first study
to present successful engraftment of anti-HIV-1
gene-modified human HSPCs in HIV-1-in-
fected humanized mice.
Accumulated evidence suggests that the current
anti-retroviral drug therapy cannot provide a
cure for AIDS.45–47 Thus far, the first and only
clinical cure ofHIV/AIDSwas achieved by trans-
plants of CCR5D32/D32 homozygous HIV-1-
resistant donor BM cells.8–11 However, wider
clinical application of such a protocol is imprac-
tical due to scarcity of HLA-matched allogeneicCCR5D32/D32 homozygous BMdonors.48,49 AutologousHSPC-based
gene therapy can eliminate the need for finding HLA type-matched
allogeneic CCR5D32/D32 homozygous BM donors. It has a potential
to develop as a novel therapeutic strategy for an HIV-1 cure. To better
evaluate the potential of anti-HIV-1 HSPC-based gene therapy strate-
gies, it is desirable to examine in a clinically relevant setting. Our newly
developed method to reconstitute HIV-1 already infected humanized
mice with anti-HIV-1 gene-modified HSPCs will be a useful tool to
investigate various anti-HIV-1 HSPC-based gene therapy strategies
in vivo in an experimentally tractable, small animal model system.
MATERIALS AND METHODS
Human CD34+ HSPCs and Fetal Tissue
Human fetal thymuses and fetal livers were obtained from Advanced
Bioscience Resources (ABR), FPA Women’s Health, and the UCLAs & Clinical Development Vol. 9 June 2018 27
Figure 5. Selective Advantage of Anti-HIV-1 Gene shRNA-Modified Human CD4+ T Lymphocytes in Tissues in HIV-1 Previously Infected Humanized Mice
The levels of %EGFP+ and %mCherry+ in human CD4+ lymphocytes were compared in bone marrow (BM), lung, gut, spleen, and human thymus implant (Hu thymus)
12 weeks after vector-modified CD34+ HSPC transplant in mock (HIV-1-uninfected) and HIV-1 pre-infected (HIV-1-infected) mice. The horizontal bars represent the mean
value. The vertical bars represent the SE. *p < 0.05, **p < 0.01, NS, not significant.
Molecular Therapy: Methods & Clinical DevelopmentCenter for AIDS Research (CFAR) Gene and Cellular Therapy Core.
The UCLA institutional review board has determined that these tis-
sues are not human subjects and do not require an institutional review
board review, because fetal tissues were obtained without patient-
identifying information from deceased fetuses. Written informed
consent was obtained from patients for the use of tissues in research
purposes. CD34+ HSPCs were isolated from fetal livers using anti-
CD34+ magnetic bead-conjugated monoclonal antibodies (Miltenyi
Biotec) and cryopreserved in Bambanker (Wako Chemical USA).28
Human thymus pieces from the same donor were cryopreserved in
10%DMSO (Sigma-Aldrich) in humanAB serum and stored in liquid
nitrogen, as previously published.39 They were thawed at 37C in a
water bath before use.
Humanized Mice
NSG mice were maintained at the UCLA CFAR Humanized Mouse
Core laboratory in accordance with a protocol approved by the
UCLA Animal Research Committee. All experiments conform to all
relevant regulatory standards. Neonatal NSG mice (1–3 days old)
were irradiated (125 cGy) and transplanted with human fetal liver
CD34+ HSPCs (0.5  105–1.0  105 cells per mouse) by intrahepatic
injection.
HIV-1 Infection
CCR5-tropic HIV-1NFNSX stocks were prepared by a calcium phos-
phate plasmid DNA transfection method as previously described.2828 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201Humanized NSG mice were injected with HIV-1NFNSX (200 ng
of p24 Gag) via the retro-orbital vein plexus using a 27-gauge
needle.Viral Load Assay
Levels of HIV-1 RNA in plasma of infected humanized mice were
determined by RT-PCR assay. 100 mL of whole blood was harvested
via the retro-orbital vein plexus 3 weeks after HIV-1 injection.
Approximately 50 mL of plasma was separated from peripheral blood
and stored at 80C until use. Viral RNA was isolated with a
QIAamp viral RNA mini kit (QIAGEN). The RNA was eluted in
25 mL of RNase-free water, and 5 mL of elution was applied for
qRT-PCR using an iScript One-step RT-PCR kit (Bio-Rad), with
the following primers and probe specific to HIV-1NFNSX gag region:
primer sequence 1, 50-CCCTACCAGCATTCTGGACATAAG-30;
primer sequence 2, 50-GCTTGCTCGGCTCTTAGAGTT-30; and
probe 50-FAM-ACAAGGACCAAAGGAACCCTT-BHQ1-30. With
these primers and probe, HIV-1 RNA can be quantitatively detected
from 103 to 108 copies/mL.Lentiviral Vector Production
Vesicular stomatitis virus G protein (VSVG)-pseudotyped lentivi-
ral vector stocks were produced by calcium phosphate-
mediated transient transfection of HEK293T cells, as previously
described.15,28,34 Vector stocks were titered on HEK293T cells8
AB
Figure 6. CCR5 Downregulation in Human CD4+ T
Lymphocytes in Tissues
The level of CCR5 expression was compared in EGFP+
and mCherry+ human CD4+ T lymphocytes in multiple
lymphoid tissues 12 weeks after vector-modified CD34+
HSPC transplant. (A) Representative data showing CCR5
downregulation in bone marrow (BM), lung, gut, spleen,
and human thymus implant (Hu thymus) under the kidney
capsule from the mock (HIV-1-uninfected) humanized
mouse (upper panels) and the HIV-1 previously infected
(HIV-1-infected) humanized mouse (lower panels). (B)
CCR5 expression was compared in EGFP+ andmCherry+
CD4+ T lymphocytes from all mice. We normalized the
CCR5 expression level using the mean CCR5 expression
in mCherry+ cells from peripheral blood (PB) as 1, using
the same method as in our previous publication.28
The horizontal bars represent the mean. The vertical
bars represent the SE. *p < 0.05. **p < 0.01. NS, not
significant.
www.moleculartherapy.org
Molecular Therapy: Methods & Clinical Development Vol. 9 June 2018 29
Molecular Therapy: Methods & Clinical Developmentbased on EGFP or mCherry expression analyzed by flow cytomet-
ric analysis.
Lentiviral Vector Transduction
The cryopreserved, fetal liver-derived CD34+ HSPCs (0.5 106) were
thawed and seeded into 20 mg/mL RetroNectin (Clontech Labora-
tories)-coated plates with 2% BSA (Sigma-Aldrich) in Yssel’s medium
(GEMINI Bio Products). After 1 hr of incubation, cells were trans-
duced with either anti-HIV-1 dual sh1005/sh516 (MOI = 3) or no-
shRNA control lentiviral vector (MOI = 1) overnight without cytokine
stimulations to achieve the similar transduction efficiencymeasured by
%EGFP or %mCherry expression, respectively. An aliquot of each
transduced CD34+ HSPC was cultured in RPMI 1640 (Gibco) with
10% fetal bovine serum (HyClone), supplemented with cytokine stim-
ulations (SCF, IL-3, and IL-6; all three from PeproTech) at a concen-
tration of 50 ng/mL for 3 days. The efficiencies of vector transduction
were evaluated by flow cytometry (Fortessa flow cytometers, BD
Biosciences). After transduction, vector-transduced CD34+ HSPCs
were mixed at a 1:1 ratio for transplantation into mice.
Transplantation of Anti-HIV-1 Gene-Modified CD34+ HSPCs
and Thymus Implantation in Humanized Mice Already Infected
with HIV-1
HIV-1-infected and mock-infected humanized NSG mice were mye-
loablated by an injection of busulfan (35 mg/kg) (Sigma-Aldrich) in
the peritoneal cavity one day before transplant. An equal mixture
of vector-transduced CD34+ HSPCs (0.5  106) was solidified with
5 mL of Matrigel (BD Biosciences). CD34 cells (4.5  106) were
also mixed in the Matrigel as feeder cells. The Matrigel-solidified
cell mix was implanted with a piece of thymus under the kidney
capsule. On the same day, mice were injected with the vector-trans-
duced human CD34+ HSPCs (0.5  106) using a 27-gauge needle
through the retro-orbital vein plexus.
Flow Cytometry
Isolation of peripheral blood mononuclear cells (PBMCs) and cells
from the BM, lung, gut, spleen, and human thymus implant were
described previously.28 Peripheral blood- and tissue-derived mono-
nuclear cells were stained with monoclonal antibodies to human
CD45-eFluor 450 (HI30, eBioscience), CD3-APC H7 (SK7, Pharmin-
gen), CD4-APC (OKT4, eBioscience), and CD8-PerCP Cy5.5 (SK1,
BioLegend), CD19-Brilliant Violet 605 (HIB19, BD Horizon), and
CCR5-PECy7 (2D7, Pharmingen). Red blood cells were lysed with
red cell lysis buffer after cell surface marker staining. Stained cells
were fixed with 1% formaldehyde in PBS and examined with Fortessa
flow cytometers (BD Biosciences). The data were analyzed by FlowJo
v.10 (Tree Star) software.
Statistical Analysis
A linear mixed-effects model was used to evaluate differences in log-
transformed EGFP or mCherry marker intensity levels by HIV status
at (1) baseline and (2) over time in Figure 4. The difference between
groups and time was evaluated using a group-time interaction, and
the p value for this interaction was calculated using a likelihood ratio30 Molecular Therapy: Methods & Clinical Development Vol. 9 June 201test comparing themodelswith andwithout the interaction term.Given
that therewere three time points, timewasmodeled as a categorical var-
iable. A compound symmetry correlation structure was used for all
models. The paired Student’s t testwas used for other statistical analysis.
Statistical significancewas evaluated as *p < 0.05.We indicate other sig-
nificance levels as follows: **p < 0.01, ***p < 0.001, and ****p < 0.0001.
Statistical analyses were performed using GraphPad Prism.
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